These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31019091)

  • 1. Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane.
    Wang Q; Pechersky Y; Sagawa S; Pan AC; Shaw DE
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9390-9399. PubMed ID: 31019091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch-like activation of Bruton's tyrosine kinase by membrane-mediated dimerization.
    Chung JK; Nocka LM; Decker A; Wang Q; Kadlecek TA; Weiss A; Kuriyan J; Groves JT
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10798-10803. PubMed ID: 31076553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.
    Wang Q; Vogan EM; Nocka LM; Rosen CE; Zorn JA; Harrison SC; Kuriyan J
    Elife; 2015 Feb; 4():. PubMed ID: 25699547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.
    Duarte DP; Lamontanara AJ; La Sala G; Jeong S; Sohn YK; Panjkovich A; Georgeon S; Kükenshöner T; Marcaida MJ; Pojer F; De Vivo M; Svergun D; Kim HS; Dal Peraro M; Hantschel O
    Nat Commun; 2020 May; 11(1):2319. PubMed ID: 32385234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E41K mutation activates Bruton's tyrosine kinase by stabilizing an inositol hexakisphosphate-dependent invisible dimer.
    Chowdhury S; Chakraborty MP; Roy S; Dey BP; Gangopadhyay K; Das R
    J Biol Chem; 2024 Jul; 300(8):107535. PubMed ID: 38971313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.
    Xu B; Liang L; Jiang Y; Zhao Z
    J Mol Graph Model; 2024 Jan; 126():108623. PubMed ID: 37716293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton's Tyrosine Kinase via Molecular Dynamics Simulations.
    Yu X; Qiu S; Sun D; Guo P; Li Q
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of Bruton's tyrosine kinase-mediated recruitment and regulation of TFII-I.
    Sacristán C; Tussié-Luna MI; Logan SM; Roy AL
    J Biol Chem; 2004 Feb; 279(8):7147-58. PubMed ID: 14623887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor.
    Lee KW; Lee WH; Han BS; Lee JH; Doo EK; Kim JH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357562
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure of the PH domain from Bruton's tyrosine kinase in complex with inositol 1,3,4,5-tetrakisphosphate.
    Baraldi E; Djinovic Carugo K; Hyvönen M; Surdo PL; Riley AM; Potter BV; O'Brien R; Ladbury JE; Saraste M
    Structure; 1999 Apr; 7(4):449-60. PubMed ID: 10196129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.
    Li T; Tsukada S; Satterthwaite A; Havlik MH; Park H; Takatsu K; Witte ON
    Immunity; 1995 May; 2(5):451-60. PubMed ID: 7538439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases.
    Li Z; Wahl MI; Eguinoa A; Stephens LR; Hawkins PT; Witte ON
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13820-5. PubMed ID: 9391111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
    Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
    Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
    Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
    Front Immunol; 2018; 9():2027. PubMed ID: 30237801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-targeting pleckstrin homology domain turns its autoinhibitory face toward the TEC kinases.
    Amatya N; Wales TE; Kwon A; Yeung W; Joseph RE; Fulton DB; Kannan N; Engen JR; Andreotti AH
    Proc Natl Acad Sci U S A; 2019 Oct; 116(43):21539-21544. PubMed ID: 31591208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Skaddan MB; Wooten DW; Wilcox KC; Voorbach MJ; Reuter DR; Jia ZJ; Foster-Duke KD; Hickson JA; Vaidyanathan S; Reed AD; Tovcimak AE; Guo Q; Comley RA; Lee L; Finnema SJ; Mudd SR
    Mol Imaging Biol; 2022 Oct; 24(5):830-841. PubMed ID: 35482146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases.
    Rawlings DJ; Scharenberg AM; Park H; Wahl MI; Lin S; Kato RM; Fluckiger AC; Witte ON; Kinet JP
    Science; 1996 Feb; 271(5250):822-5. PubMed ID: 8629002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.